Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Duality Biotherapeutics, Inc. ( (HK:9606) ).
Duality Biotherapeutics shareholders have approved the company’s new 2025 Share Scheme at an extraordinary general meeting held on 30 December 2025, passing all three ordinary resolutions by a clear majority via poll. The resolutions authorize the adoption and administration of the equity incentive plan, including the power to allot and issue shares for award vesting, set an overall scheme mandate limit and a specific sublimit for service providers, and seek listing approval for any new shares, thereby strengthening the company’s ability to grant share-based incentives to employees and partners without any shareholder opposition or required abstentions.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$493.00 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a Cayman Islands-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of therapeutic products, with its shares traded under stock code 9606.
Average Trading Volume: 1,321,283
Technical Sentiment Signal: Hold
Current Market Cap: HK$27.82B
See more data about 9606 stock on TipRanks’ Stock Analysis page.